Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
John Weinberg, MD, COO, Veloxis Pharmaceuticals, describes the benefits of the Veloxis’ Envarsus, an orphan drug for the treatment of organ transplant rejection. Envarsus is a reformulation of tacrolimus,…
John Weinberg, MD, COO, Veloxis Pharmaceuticals describes the challenges of organ transplantation. While advancements in the field have minimized the short-term risks of transplantation, the average kidney transplant only lasts…
Yaron Daniely, PhD, MBA, CEO of Alcobra Pharma, talks about the problems with current medications for ADHD. First class medications against ADHD include scheduled stimulants such as Ritalin, Adderall,…
Martin Lee, director, Project CBD, talks about the JAMA article that highlights the 25 percent decrease in overdose deaths from opiates in states where medical marijuana is legal. According…
Martin Lee, director, Project CBD talks about the medical benefits of cannabidiol (CBD). CBD is the non-psychoactive compound in cannabis, and can serve as an effective therapy for cardiovascular disease,…
John Weinberg, MD, COO, Veloxis Pharmaceuticals, talks about the challenges in current organ transplantation methods, and Veloxis’ once-daily solution to advancing kidney transplantation. According to Weinberg, most kidney transplants…
Jose Cavazos, MD, Professor of Medicine – Neurology & Physiology, Associate Professor of Pharmacology at University of Texas Health Science Center at San Antonio, discusses responsive neurological stimulation…
Agitation is common in patients with Alzheimer’s disease. It is often expressed as aggression, excessive activity or hostility. A new study examined whether the anti-depressant drug citalopram is…
Steven Mento, PhD, Co-Founder, President & CEO, Conatus Pharmaceuticals, addresses the need for a better understanding of the causes of liver disease. Conatus’s latest project, Emricasan, a therapy for…
